Navigation Links
Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709

ugh the oral route is not excluded as an option, targeted delivery, which could be developed with appropriate players in this field, could have the added benefit of avoiding unnecessary systemic exposure."

AR-709 is a novel DHFR inhibitor with an outstanding microbiological activity against streptococci in general and, importantly, against multi-drug resistant Streptococcus pneumoniae, the most relevant pathogen in community-acquired pneumonia. Moreover the compound has been shown to be highly effective in preclinical pneumonia models of infection both intravenously and by the oral route.

Arpida is completing the appropriate studies in order to initiate tolerability studies in humans.

About Streptococcus pneumoniae and pneumonia

Streptococcus pneumoniae is the most feared bacterium that causes pneumonia in the community setting. Since the first reports of Streptococcus pneumoniae resistance to penicillin in 1967, the number of multiple antibiotic resistant organisms has rapidly increased world-wide, reaching peaks of 80% in regions of some countries in 1998. In the USA, up to 40% of the bacterial strains causing these infections are resistant to at least one drug, and 15% are resistant to three or more commonly used drugs. Streptococci cause 500,000 cases of pneumonia each year, and 7 million cases of ear infections and sinusitis in the USA alone. Recently, epidemics of diseases caused by Streptococcus pneumoniae have reappeared in settings such as chronic care facilities, military camps and day care centers, a situation not seen since the pre-antibiotic era.

This increasing number of antibiotic-resistant pathogens is of specific concern to physicians in the area of respiratory tract infection. In the community setting, 67% of antibiotic use in adults and 87% in children is for the treatment of RTIs. The antibacterial market in the community settings is estimated at USD18 billion with pneumonia acquired in the community setting acc
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Arpida adds novel antibiotic AR-2474 to its preclinical pipeline
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Arpida Announces Promising Results First Man Studies With
(Date:12/24/2014)...  Lockton Dunning Benefits, the Dallas ... addition of Vice President Kim Foerster ... Consulting team, Excelsior Solutions. Foerster ... the position.  Most recently, she worked as the ... Pharmacy, where she has held various managerial positions ...
(Date:12/24/2014)... Tianyin Pharmaceutical Co., Inc. (NYSE MKT: ... biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... the Company achieved the Public Notice (Gong Shi) ... of TPI,s Qionglai Facility (QLF) from the China ... period is a significant procedure of GMP certification ...
(Date:12/24/2014)... DUBLIN and RALEIGH, N.C. ... subsidiary of Endo International plc (NASDAQ: ENDP ... BDSI ) announced today that they have ... Buccal Film to the U.S. Food and Drug Administration ... the management of pain severe enough to require daily, ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... May 2, 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ... Ltd. (NASDAQ: TEVA ) and Cephalon, Inc. (NASADQ: ... acquired by Teva.  In response to the news, Valeant has ... this announcement is positive news for Cephalon stockholders and we ...
... SAN JOSE, Calif., May 2, 2011 EMBEDDED SYSTEMS ... company, announces the availability of Prism FP ™ , ... lossless compression of floating point data types.   ... thousands or tens of thousands of computing nodes poses ...
Cached Medicine Technology:Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction 2Samplify Systems Announces Availability of Prism FP Floating Point Compression 2
(Date:12/25/2014)... Phoenix, AZ (PRWEB) December 25, 2014 ... comes to outstanding customer service and affordable quality regarding ... metropolitan area announces recognition in 2014 by the “Queen ... and Sons has earned an impressive reputation over the ... pricing on a wide range of contractor services for ...
(Date:12/24/2014)... Connie Casad, MD, a well-known and ... with 30 years of practice experience in Dallas, Texas, ... benefits of dietary detoxification. The second study is scheduled ... results from test patients who just completed a 21-day ... interest in conducting the study, Dr. Casad said, "About ...
(Date:12/24/2014)... 2014 Dr. Vu Ho, a Dallas ... his practice and med-spa with the addition of new ... of cosmetic treatments and services. , “Silk Peel is ... says Dr. Ho. “As a result it can address ... sun spots, discolorations or blemishes.” , Similar to microdermabrasion, ...
(Date:12/24/2014)... Dallas, TX (PRWEB) December 25, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. Stivarga is a drug which is ... This drug is orally administered and is also prescribed ... The drug which is FDA approved is a multi-kinase ...
(Date:12/24/2014)... 24, 2014 (HealthDay News) -- The holidays can be a ... off by certain foods and drinks. "This is the ... trigger attacks of migraine," Dr. David Dodick, chair of the ... foundation. "It,s important to think through food and beverage ... attack," added Dodick, a professor of neurology at the Mayo ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Expert Offers Tips for Preventing Holiday Migraines 2
... 15th, on Capitol Hill, the Center for Medicine in ... a question-and-answer session for media and Congressional Staff entitled: ... Experts Discuss Patient Safety." The event will be co-hosted ... Commerce Committee, Congresswoman Anna Eshoo (D-CA) and Congressman Mike ...
... have long been committed to expanding coverage to the millions ... know all too well what lack of coverage means for ... rooms every day. As a nation, we know we can ... with Chairman Baucus and the Obama Administration to move comprehensive ...
... ANGELES, July 8 Social Compassion in Legislation ... pet overpopulation through legislation, today reported that the total ... municipal shelters increased 14.6 percent statewide - from 378,445 ... released figures from the California Department of Public Health ...
... , WASHINGTON, July 8 Today, the American Hospital ... announced an agreement with the White House and Senate ... spending by $155 billion. Cost savings is an ... the national association representing physician owned hospitals. As always, ...
... says, , WEDNESDAY, July 8 (HealthDay News) -- Scientists ... monoclonal antibody drug might safely cure anthrax poisoning in ... they are not effective in killing the toxins produced ... those toxins once they enter the bloodstream. After an ...
... 8 Watson Pharmaceuticals, Inc. (NYSE: WPI ... today announced that its subsidiary, Watson Laboratories, Inc., has ... Administration to market its over-the-counter Nicotine Polacrilex Gum USP, ... fruit and cinnamon flavors. , , Nicotine Polacrilex ...
Cached Medicine News:Health News:CMPI to Host Hill Briefing on Follow-On Biologic Drugs for Media and Congressional Staff with Reps. Eshoo and Rogers 2Health News:Statement About Agreement With White House and Senate Finance Committee on Health Reform 2Health News:California Department of Public Health Reports Large Increase in Pet Euthanasia 2Health News:California Department of Public Health Reports Large Increase in Pet Euthanasia 3Health News:Physician Hospitals of America Charges: Hospital Associations Bargain Away $155 Billion in Medicare Funding in Attempt to Destroy Physician Hospitals 2Health News:Physician Hospitals of America Charges: Hospital Associations Bargain Away $155 Billion in Medicare Funding in Attempt to Destroy Physician Hospitals 3Health News:New Drug Fights Anthrax Toxin 2Health News:New Drug Fights Anthrax Toxin 3Health News:Watson Pharmaceuticals Receives FDA Approval for Fruit and Cinnamon Flavored Coated Nicotine Gums 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: